Tumor cells tend to behave differently in response to immune selective conditions. Contrary to those in therapeutic antitumor conditions, tumor cells in prophylactic antitumor conditions lose antigen expression for antitumor immune escape. Here, using a CT26/HER2 tumor model, we investigate the underlying mechanism(s). We selected tumor cell variants (CT26/HER2-A1 and -A2) displaying resistance to antitumor protective immunity and loss of HER2 antigen expression. These immune-resistant cells failed to induce Ag-specific IgG and IFN-γ responses while forming tumors at the same rate as CT26/HER2 cells. RT-PCR, qRT-PCR, PCR, Western blot and DNA sequencing analyses demonstrated that HER2 expression was inhibited at the post-transcriptional level in these immune-resistant cells, suggesting that tumor cells may escape antitumor immunity through the post-transcriptional regulation of antigen gene expression. The proteasome and lysosomal protein degradation pathways were not responsible for antigen loss, as determined by an inhibitor assay. Finally, HER2 mRNA was found to be not present in the monosomes and polysomes of CT26/HER2-A2 cells, as opposed to CT26/HER2 cells, suggesting that the translation activity of HER2 mRNAs may be suppressed in these immune-resistant cells. Taken together, our results report a new mechanism by which tumor cells respond to antitumor protective immunity for antitumor immune evasion.

No abstract

Postherpetic neuralgia (PHN) is the most common but challenging complication of herpes zoster due to long-lasting intractable neuropathic pain. Routine pharmacologic treatments of PHN include anticonvulsants (e.g., gabapentin, pregabalin), antidepressants (e.g., amitriptyline), opioids (e.g., oxycodone, morphine). However, those medications have limitations due to side effects inclusive of peripheral edema, nausea, vomiting and somnolence, or insufficient analgesic effect. Mirogablin, a novel voltage-gated calcium channel (VGCC) selective α 2 δ ligand, has been recently approved as a drug to treat peripheral neuropathic pain. In this case report, we represent a 77-year-old patient with intractable PHN who achieved successful pain relief with intake of mirogabalin with less side effects.

Purpose The purpose of this study was to develop a psychic energy management scale that construct a concept and based on extracted contents of structural validity and reliability of university athlete psychic energy management inventory. Methods To develop the scale, the researches were completed <research ⅰ; constructing sub-factors of Psychological Energy Management, ⅱ; developing scales of psychic energy management, ⅲ; verifying validity of psychic energy management>. The results shown are a follows. Results The psychic energy management inventory contents of the university athlete were categorized into five categories ; team energy, game energy, environment energy, leisure energy and body energy. Through statistical procedures and factor analysis, the psychic energy management inventory was developed with 4 factors 18 items (coach energy 4 question items, game/environment energy 6 question items, colleague energy 4 question items, body energy 4 question items). Conclusion Convergent validity and discriminant validity was demonstrated through the external validity, the multi-group analysis confirmed the structural equivalence of the scale between the school grades.

No abstract